$318 Million is the total value of EcoR1 Capital, LLC's 31 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | JAZZ PHARMACEUTICALScall | $26,594,000 | – | 189,200 | +100.0% | 8.35% | – | |
| KURA | New | KURA ONCOLOGY INC | $20,580,000 | – | 2,450,000 | +100.0% | 6.46% | – |
| CYTK | New | CYTOKINETICS INC | $14,840,000 | – | 1,418,700 | +100.0% | 4.66% | – |
| GLPG | New | GALAPAGOSsponsored adr | $10,524,000 | – | 167,361 | +100.0% | 3.30% | – |
| IRWD | New | IRONWOOD PHARMACEUTICALS | $9,522,000 | – | 821,531 | +100.0% | 2.99% | – |
| New | RETROPHIN INCcall | $4,709,000 | – | 244,100 | +100.0% | 1.48% | – | |
| OVAS | New | OVASCIENCE INC | $4,152,000 | – | 424,979 | +100.0% | 1.30% | – |
| New | CYTOKINETICS INCcall | $2,977,000 | – | 284,600 | +100.0% | 0.94% | – | |
| ZFGN | New | ZAFGEN INC | $2,321,000 | – | 369,000 | +100.0% | 0.73% | – |
| NRXGQ | New | NEPHROGENEX INC | $941,000 | – | 588,235 | +100.0% | 0.30% | – |
| New | ZAFGEN INCcall | $63,000 | – | 10,000 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-03 |
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.